1 / 11

Comparison of the Visian Implantable Collamer Lens with the Verisyse Phakic Intraocular Lens in High Myopia

Comparison of the Visian Implantable Collamer Lens with the Verisyse Phakic Intraocular Lens in High Myopia . Jigna Joshi MD Marian Macsai MD Parag Majmudar MD Vanee Virasch MD A Collaboration between Northwestern and Rush University.

wilbur
Download Presentation

Comparison of the Visian Implantable Collamer Lens with the Verisyse Phakic Intraocular Lens in High Myopia

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Comparison of the Visian Implantable Collamer Lens with the Verisyse Phakic Intraocular Lens in High Myopia Jigna Joshi MD Marian Macsai MD Parag Majmudar MD Vanee Virasch MD A Collaboration between Northwestern and Rush University Dr. Macsai is a member of the speakers bureau for Allergan and Alcon. Dr. Majmudar is a consultant for AMO.

  2. Purpose • To compare outcomes of the Visian Implantable Collamer Lens with the Verisyse Phakic Intraocular Lens in patients with high myopia

  3. Methods • A retrospective chart review of consecutive patients implanted with a phakic intraocular lens by one of two experienced surgeons.

  4. Results

  5. Results

  6. Results

  7. Results • Average loss of endothelial cells in the first 12 months was 4.4% in the Verisyse group and 2.5% in the Visian group. • Six (6) patients (8%) in the Verisyse group required enhancements with either PRK or LASIK • Four (4) patients (7.1%) in the Visian group required enhancement with LASIK.

  8. Results • Three eyes required enlargement of Yag peripheral iridotomies within the first post operative month in the Visian group. • Four eyes developed mild peripheral anterior subcapsular opacities that were not visually significant in the Visian group. • No lenses required explantation

  9. Limitations • Small sample size • Endothelial cell counts in the Verisyse group were measured by two different techniques, one pre-op and one post-op, resulting in higher variability in that group • The inherent difference in lens position will result in different complications

  10. Conclusion • Visual outcomes were similar in both intraocular lens groups. • Enhancement rates for residual refractive errors were similar in both intraocular lens groups. • Rate of endothelial cell loss was greater in the Verisyse, while the Visian group had more capsular opacities (visually insignificant).

  11. Conclusion • The Visian ICL and the Verisyse Phakic IOL appear to be safe alternatives for the treatment of high myopia. • Post market approval outcomes are helpful for physicians considering including these techniques in their practice.

More Related